Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis

Journal of Clinical Investigation

Volumn 126, Issue 4, 2016, Pages 1458-1470

  Demehri, Shadmehr ^a,b   Cunningham, Trevor J ^a,b   Manivasagam, Sindhu ^b   Ngo, Kenneth H ^a   Tuchayi, Sara Moradi ^a   Reddy, Rasika ^b   Meyers, Melissa A ^b   DeNardo, David G ^b   Yokoyama, Wayne M ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; FAS LIGAND; GRANZYME B; INTERLEUKIN 6; INTERLEUKIN 8; THYMIC STROMAL LYMPHOPOIETIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; CYTOKINE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST; BREAST CANCER; BREAST CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH2 CELL; TUMOR MICROENVIRONMENT; ANIMAL; CELLULAR IMMUNITY; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; PATHOLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; IMMUNITY, CELLULAR; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; TH2 CELLS; TUMOR SUPPRESSOR PROTEINS;

EID: 84964644394     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83724     Document Type: Article

References (37)

1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480-489.
2. Criscitiello C, Curigliano G. Immunotherapeutics for breast cancer. Curr Opin Oncol. 2013;25(6):602-608.
3. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67(19):9518-9527.
4. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
5. Lo Kuan E, Ziegler SF. Thymic stromal lymphopoietin and cancer. J Immunol. 2014;193(9):4283-4288.
6. Ziegler SF. Thymic stromal lymphopoietin and allergic disease. J Allergy Clin Immunol. 2012;130(4):845-852.
7. Demehri S, Turkoz A, Manivasagam S, Yockey LJ, Turkoz M, Kopan R. Elevated epidermal thymic stromal lymphopoietin levels establish an antitumor environment in the skin. Cancer Cell. 2012;22(4):494-505.
8. Di Piazza M, Nowell CS, Koch U, Durham AD, Radtke F. Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting. Cancer Cell. 2012;22(4):479-493.
9. Cipolat S, Hoste E, Natsuga K, Quist SR, Watt FM. Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility. Elife. 2014;3:e01888.
10. Pedroza-Gonzalez A, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med. 2011;208(3):479-490.
11. Li M, Hener P, Zhang Z, Kato S, Metzger D, Chambon P. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci U S A. 2006;103(31):11736-11741.
12. Sato-Deguchi E, Imafuku S, Chou B, Ishii K, Hiromatsu K, Nakayama J. Topical vitamin D(3) analogues induce thymic stromal lymphopoietin and cathelicidin in psoriatic skin lesions. Br J Dermatol. 2012;167(1):77-84.
13. Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. PLoS Biol. 2009;7(5):e1000067.
14. Zhang Z, et al. Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc Natl Acad Sci U S A. 2009;106(5):1536-1541.
15. Vena JE, Bona JR, Byers TE, Middleton E Jr, Swanson MK, Graham S. Allergy-related diseases and cancer: an inverse association. Am J Epidemiol. 1985;122(1):66-74.
16. Hedderson MM, Malone KE, Daling JR, White E. Allergy and risk of breast cancer among young women (United States). Cancer Causes Control. 2003;14(7):619-626.
17. Wang H, Diepgen TL. Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy. 2005;60(9):1098-1111.
18. Lee EB, Kim KW, Hong JY, Jee HM, Sohn MH, Kim KE. Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. Pediatr Allergy Immunol. 2010;21(2 pt 2):e457-e460.
19. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007;7(9):659-672.
20. Demehri S, et al. Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a sentinel for epidermal integrity. PLoS Biol. 2008;6(5):e123.
21. Tarulli GA, et al. Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium. Breast Cancer Res. 2013;15(1):R10.
22. Osuala KO, et al. Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC Cancer. 2015;15:584.
23. Singh JK, Simoes BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013;15(4):210.
24. Kim BS, et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med. 2013;5(170):170ra116.
25. Kitajima M, Ziegler SF. Cutting edge: identification of the thymic stromal lymphopoietinresponsive dendritic cell subset critical for initiation of type 2 contact hypersensitivity. J Immunol. 2013;191(10):4903-4907.
26. Engelhardt JJ, et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell. 2012;21(3):402-417.
27. DeNardo DG, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16(2):91-102.
28. Olkhanud PB, et al. Thymic stromal lymphopoietin is a key mediator of breast cancer progression. J Immunol. 2011;186(10):5656-5662.
29. De Monte L, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208(3):469-478.
30. Hingorani SR, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437-450.
31. Calderon B, Carrero JA, Unanue ER. The central role of antigen presentation in islets of Langerhans in autoimmune diabetes. Curr Opin Immunol. 2014;26:32-40.
32. Strid J, Sobolev O, Zafirova B, Polic B, Hayday A. The intraepithelial T cell response to NKG2Dligands links lymphoid stress surveillance to atopy. Science. 2011;334(6060):1293-1297.
33. Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol. 2010;11(4):289-293.
34. Johansson M, Denardo DG, Coussens LM. Polarized immune responses differentially regulate cancer development. Immunol Rev. 2008;222:145-154.
35. Masannat YA, Bains SK, Pinder SE, Purushotham AD. Challenges in the management of pleomorphic lobular carcinoma in situ of the breast. Breast. 2013;22(2):194-196.
36. Schnitt SJ. Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr. 2010;2010(41):158-161.
37. Yu H, Yang J, Li Y, Jiao S. [The expression of thymic stromal lymphopoietin in primary tumors of breast cancer is associated with prognosis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015;31(2):239-243.